Oncolytics Biotech Inc. (Nasdaq: ONCY) received an FDA nod to proceed with phase 3 trial of its head and neck cancer treatment sending the stock price soaring 60 cents to close at $3.54.
FDA Approves Next Phase Trial For Oncolytics Drug
October 02, 2009 at 17:38 PM EDT
